Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 7/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 6/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 3/20 | 0.43 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6142180 | 0.78 | CYP3A4 (0.48) | MAPTKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL7027606 | 0.75 | MAPT (0.50) | MAPTKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL6142388 | 0.74 | LMNA (0.49) | MAPTKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL7032103 | 0.72 | ALDH1A1 (0.41) | MAPTKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL6969203 | 0.71 | ADRA2A (0.51) | MAPTKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL3070366 | 0.69 | LMNA (0.63) | MAPTKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL5540587 | 0.69 | MMP2 (0.59) | MAPTKMT2ASMN1; SMN2MEN1TDP1 | |
| SCHEMBL4349747 | 0.68 | MMP2 (0.56) | MAPTSMN1; SMN2TDP1ALDH1A1KDM4E | |
| SCHEMBL8404537 | 0.68 | LMNA (0.68) | MAPTSMN1; SMN2TDP1NPC1ALDH1A1 | |
| SCHEMBL10515967 | 0.67 | MAPT (0.51) | MAPTKMT2AMEN1TDP1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944601-B1 | GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2003-02-12 | — | — | EP | claimed |
| US-20020095039-A1 | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-07-18 | — | — | US | claimed |
| US-20020028950-A1 | Guanidinylamino heterocycle compunds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-03-07 | — | — | US | claimed |
| US-6306877-B1 | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE CO. | 2001-10-23 | — | — | US | claimed |
| US-6172095-B1 | DECONGESTANTS, ANALGESICS, HYPOTENSIVE AGENTS; TREATING HEADACHES, OTITIS MEDIA, SINUSITUS, GASTROINTESTINAL AND RESPIRATORY SYSTEM DISORDERS; SIDE EFFECT REDUCTION | THE PROCTER & GAMBLE COMPANY | 2001-01-09 | — | — | US | claimed |
| EP-0944601-A1 | GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | claimed |
| WO-1998023591-A1 | GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| US-6610720-B2 | Administering to the patient an alpha-2 adrenoreceptor agonist for the treatment or prevention of emesis | MERCK FROSST CANADA & CO. (CA) | 2003-08-26 | — | — | US | disclosed |
| EP-0944601-B1 | GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | PROCTER & GAMBLE (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6436978-B1 | FOR PREVENTING OR TREATING DISORDERS MODULATED BY ALPHA-2 ADRENOCEPTORS | THE PROCTER & GAMBLE CO. | 2002-08-20 | — | — | US | disclosed |
| US-20020095039-A1 | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-07-18 | — | — | US | disclosed |
| US-20020045565-A1 | Method for treating or preventing emesis | MERCK FROSST CANADA LTD. (CA) | 2002-04-18 | — | — | US | disclosed |
| US-20020028950-A1 | Guanidinylamino heterocycle compunds useful as alpha-2 adrenoceptor agonists | CUPPS THOMAS LEE (US) | 2002-03-07 | — | — | US | disclosed |
| US-6306877-B1 | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists | THE PROCTER & GAMBLE CO. | 2001-10-23 | — | — | US | disclosed |
| US-6172095-B1 | DECONGESTANTS, ANALGESICS, HYPOTENSIVE AGENTS; TREATING HEADACHES, OTITIS MEDIA, SINUSITUS, GASTROINTESTINAL AND RESPIRATORY SYSTEM DISORDERS; SIDE EFFECT REDUCTION | THE PROCTER & GAMBLE COMPANY | 2001-01-09 | — | — | US | disclosed |
| EP-0944601-A1 | GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023591-A1 | GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045565-A1 | Method for treating or preventing emesis | ADRB2, ADRA2A, ADRA2C | MAPT 4165/4885KMT2A 2884/4885SMN1; SMN2 1580/4885 |
| US-20020095039-A1 | Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists | ADRB2, ADRA2C, ADRA2A | MAPT 318/4885KMT2A 2877/4885SMN1; SMN2 1179/4885 |
| US-20020028950-A1 | Guanidinylamino heterocycle compunds useful as alpha-2 adrenoceptor agonists | ADRB2, ADRA2C, ADRA2A | MAPT 652/4885KMT2A 2670/4885SMN1; SMN2 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.